Enveric Biosciences is a biotechnology company developing small-molecule neuroplastogenic therapeutics designed to treat psychiatric and neurological disorders by promoting neuroplasticity without hallucinogenic effects. The company leverages its proprietary Psybrary™ platform—a patent-protected chemical library encompassing approximately one million potential molecular structures—to advance a pipeline of novel compounds, with EB-003, a first-in-class DMT derivative, as its lead candidate targeting depression and anxiety. Enveric generates revenue primarily through out-licensing compounds and patent portfolios to strategic pharmaceutical partners and plans to pursue future product approvals and commercialization of approved therapies.